【Abstract】ObjectiveTo review the epidemiology, etiology, pathology, clinical presentation, diagnosis and treatment, recurrance and prognosis of Mondor disease. MethodsLiteratures on Mondor disease were reviewed, and our study of Mondor disease was also included. ResultsMondor disease is difficult to diagnose, but is with good prognosis in most patients. It’s unclear whether Mondor disease is associated with the etiology of breast cancer. ConclusionThe diagnosis and therapy of Mondor disease are important, especially when it is accompanied with breast cancer.
PURPOSE:To investigate the content of vascular endothelial growth factor (VEGF)in vitreous of patients with retinal vascula'r proliferative diseases. METHODS:The concentration of VEGF in undiluted vitreous samples from patients with retina vein occlusion (RVO) (n=7),Eales disease (n=7)and controls (n=7) was measured by enzyme linked immunosorbent assay (EL1SA). RESULTS:The levels of vitreous VEGF were significantly higher 13 folds in patients with RVO(4.67plusmn;3.38)ng/ml and 5 folds in patients with Eales disease(1.79plusmn;0.44)ng/ml than in controls (0.35plusmn;0.15)ng/ml separately(P<0. 01). CONCLUSIONS:VEGF might play a part in mediating the neovascularization of retinal vascular diseases. (Chin J Ocul Fundus Dis,1997,13:171-173)
目的:观察艾灸联合芦荟、红花、当归酒精提取液治疗输液并发静脉炎的临床疗效。方法:将60例静脉炎患者随机分为两组,观察组采用艾灸联合芦荟、红花、当归酒精提取液治疗,对照组采用50%硫酸镁治疗,并进行疗效对比。结果: 观察组痊愈22例、显效6例、有效2例、无效0例,有效率100%;对照组痊愈13例、显效8例、有效3例、无效6例,有效率80%;两组相比差异有统计学意义(Plt;0005)。结论:艾灸联合芦荟、红花、当归酒精提取液具有活血化瘀、散结止痛、抗炎解毒、促进损伤组织细胞修复作用。
目的 探讨Trivex旋切术治疗下肢血栓性浅表静脉炎的临床疗效。方法 回顾性分析67例下肢血栓性浅表静脉炎病例的临床资料。患者术前给予丹参治疗、下肢静脉造影等术前准备; 然后行大隐静脉主干内膜剥脱、用Trivex旋切系统剖吸曲张静脉和静脉丛内的血栓; 术后给予低分子肝素抗凝、早期下床活动等处理。结果 全部患者的手术均顺利,术中及术后无肺栓塞发生。术后2例切口Ⅱ期愈合, 65例切口Ⅰ期愈合。所有病例术后3d均出院,住院时间(5±1) d。15例术后患肢有瘀斑者随访2周均消失; 7例出现内踝部麻木感,随访6个月消失; 本组患者均获随访6个月,未见复发者。结论 下肢血栓性静脉炎早期行以Trivex旋切术为主的综合治疗,其临床疗效好、住院时间短、创伤小及美容效果好,并可有效防止病情反复、深静脉血栓及肺栓塞的发生,是治疗下肢血栓性静脉炎的有效手段。
Objective To assess the efficacy and safety of Hirudoid for microcirculation disorder. Methods We searched The Cochrane Library (Issue 4, 2009), PubMed, EMbase, CNKI, CBM, and VIP databases up to December 2009. Randomized controlled trials (RCTs) or quasi-RCTs concerning Hirudoid for microcirculation disorder were included. The methodological quality of the included studies was assessed according to the Cochrane Reviewer’s Handbook 5.0.1, and meta-analyses were conducted using RevMan software 5.0. Results Twenty-five RCTs were included, of which only one was graded as high quality and others were of low quality. The results of meta-analyses showed: Hirudoid could be effective in preventing the occurrence of phlebitis (OR=0.18, 95%CI 0.13 to 0.25). Hirudoid for treating phlebitis was also significantly better than magnesium sulfate or placebo (OR=7.18, 95%CI 4.59 to 11.22) and the time to symptom relief of Hirudoid was significantly shorter than placebo (MD= – 29, 95%CI – 37.30 to – 20.70). Hirudoid for internal fistula in hemodialysis patients was better than the simple hot compress (OR=8.89, 95%CI 4.25 to 18.58), and also better than the magnesium sulfate plus hot compress (OR=7.62, 95%CI 2.84 to 20.44). Hirudoid could also prevent the formation of hematoma and eliminate hematoma quickly. Hirudoid for tissue injury caused by irritating fluid extravasation was significantly better than magnesium sulfate (OR=4.25, 95%CI 2.06 to 8.78). Conclusion Hirudoid can significantly improve the microcirculation disorder, especially to the phlebitis. Due to the low quality of the included studies, further, more high quality trials are required.